My Account
Jan 18, 2021 10:47 PM IST Net Sales are expected to increase by 15.5 percent Y-o-Y (up 5 percent Q-o-Q) to Rs. 5,799.4 crore, according to Prabhudas Lilladher.
Jun 03, 2020 07:46 AM IST The stock shot up 149 percent from its March lows especially after increased focus on healthcare worldwide due to COVID-19 crisis.
Oct 14, 2019 03:47 PM IST Net Sales are expected to increase by 18.8 percent Y-o-Y (up 3.7 percent Q-o-Q) to Rs. 5,645.7 crore, according to Emkay.
Apr 17, 2019 03:10 PM IST Net Sales are expected to increase by 26.5 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 5,121.6 crore, according to Kotak.
Apr 12, 2019 12:45 PM IST Net Sales are expected to increase by 25.9 percent Y-o-Y (down 3 percent Q-o-Q) to Rs. 5,020.7 crore, according to Prabhudas Lilladher.
Feb 11, 2019 01:08 PM IST Aurobindo has maintained its guidance of 30 percent YoY growth in injectable sales. Further, company filed 10 ANDAs, including 4 injectables, taking the cumulative ANDAs pending for approval to 122
Feb 07, 2019 07:54 AM IST The company will declare its results today. Analysts suggest one to focus on US business growth and upcoming product announcements.
Jan 18, 2019 01:51 PM IST Net Sales are expected to increase by 12.7 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 4,888 crore, according to Sharekhan.
Jan 11, 2019 05:23 PM IST Net Sales are expected to increase by 15.8 percent Y-o-Y (up 5.7 percent Q-o-Q) to Rs. 5,022.3 crore, according to ICICI Direct.
Jan 04, 2019 10:45 AM IST For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.
Nov 12, 2018 08:18 AM IST Further, high R&D cost is likely to affect financials as well, one brokerage house wrote in its report.
Oct 17, 2018 05:39 PM IST Net Sales are expected to decrease by 3.9 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 4,260 crore, according to HDFC Securities.
Oct 16, 2018 06:55 PM IST Net Sales are expected to increase by 6.3 percent Y-o-Y (up 10.9 percent Q-o-Q) to Rs. 4,714 crore, according to Sharekhan.
Oct 12, 2018 03:54 PM IST Net Sales are expected to increase by 4.6 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 4,638.9 crore, according to ICICI Direct.
Aug 25, 2018 10:26 AM IST Emkay Global, in its report, observed that cycling pressure in US market will start waning ahead, but structural pressures will still persist.
Jul 18, 2018 02:06 PM IST Net Sales are expected to increase by 12 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 4,119 crore, according to Kotak.
Jul 12, 2018 09:42 PM IST "For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities
Apr 20, 2018 01:01 PM IST Net Sales are expected to increase by 13.8 percent Y-o-Y (down 5.5 percent Q-o-Q) to Rs. 4,100 crore, according to HDFC Securities.
Apr 16, 2018 05:55 PM IST Net Sales are expected to increase by 19 percent Y-o-Y to Rs. 4,334.4 crore, according to Edelweiss.
Apr 12, 2018 05:53 PM IST Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.
Feb 07, 2018 12:28 PM IST Europe and Rest of World sales are likely to grow 15-18 percent YoY while API business is likely to be flat.
Jan 18, 2018 08:36 AM IST As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
Jan 11, 2018 04:06 PM IST The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.
Nov 08, 2017 05:26 PM IST EBITDA (earnings before interest, tax, depreciation and amortisation) may increase 15.6 percent year-on-year to Rs 1,074.4 crore and margin may expand 110 basis points to 25.7 percent for quarter ended September 2017.
Oct 13, 2017 05:31 PM IST Net Sales are expected to increase by 6.9 percent Y-o-Y (up 9.7 percent Q-o-Q) to Rs. 4035.4 crore, according to Kotak.
